Boston Scientific Holds To Year-Long Guidance Despite Weak Sales In August
This article was originally published in The Gray Sheet
Boston Scientific attributes lower than expected stent sales in August to Johnson & Johnson/Cordis' increased stent supply capacity rather than the European launch of Medtronic's Endeavor drug-eluting stent
You may also be interested in...
Medtronic believes it can capture more than 15% of the international drug-eluting stent market within one year of rolling out its Endeavor in 40 countries outside the U.S
A combined final opinion on the European Chemicals Agency’s proposed microplastic restriction is expected from ECHA committees by year-end, at which point the European Commission will consider whether and when microplastic must be removed from all leave-on cosmetic products marketed in the EU.
Butterfly Network’s CEO Laurent Faracci outlines the company’s growth strategy and plans for their “ultrasound-on-a-chip” technology after its merger with blank check company Longview Acquisition Corp. See what the company’s CEO said about it here.